EMA Recommends Granting a Conditional Marketing Authorisation for Linvoseltamab By Ogkologos - April 10, 2025 377 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed and refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR ΤΙ ΕΙΝΑΙ January 18, 2019 ESMO Sarcoma and Rare Cancers Congress 2024 March 5, 2024 Beloved Jeopardy! Host Alex Trebek Has Passed Away After Battle with... November 9, 2020 Mediterranean Diet Associated with a Higher Probability of Response in Patients... February 28, 2023 Load more HOT NEWS FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumour iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with... Woman With Double Mastectomy Invents Breastfeeding Simulator For Breast Cancer Survivors NEOSTAR Results Indicate that Neoadjuvant Nivolumab Plus Ipilimumab Enhances Pathologic Responses...
